By Karen Roldán Phytosanitary regulation in Argentina is evolving toward more modern, scientific approaches that are aligned with international standards. With the entry into force of SENASA Resolution 458/2025 and its amendment 843/2025, a key opportunity has opened up for companies seeking to register new or equivalent active substances, incorporating QSAR and in silico methodologies as valid toolswithin...
By Victor Abrego The evaluation of non-mutagenic impurities (NMIs) is a critical aspect of pharmaceutical development, ensuring that products are safe for human consumption. While the ICH Q3A and Q3B guidelines establish a general framework, challenges remain in qualifying impurities that are new or at higher concentrations than previously evaluated. How do you evaluate non-mutagenic impurities and...
By Karen Roldán Nitrosamines, chemical compounds with known carcinogenic potential, have generated concern in various sectors, particularly in the pharmaceutical industry. Since their discovery in the 1950s, they have been the subject of extensive studies due to their potential adverse effects on human health. At QSAR Analytics, we understand the importance of addressing this challenge with scientific solutions...
Visit the news of our blog so that you know a little more about the topic of your interest.
